npy y2

BIIE-0246 is a selective NPY2R antagonist with an IC50 of 15 nM at the rat [125I]PYY3-36 site. It reduces NPY-stimulated expression of p-AKT S473 and P-p44/42 MAPK.

SF 11 is a potent, brain-penetrant neuropeptide Y Y2 receptor antagonist with an IC50 of 199 nM, exhibiting antidepressant-like activity.

Pancreatic Polypeptide, rat acetate is an agonist of NPY receptor, with high affinity at NPYR4.

CYM 9484 is a selective and potent neuropeptide Y (NPY) Y2 receptor antagonist with an IC50 value of 19 nM.

SF-22 is a neuropeptide Y receptor (Y2R) antagonist that crosses the blood-brain barrier and has potential anti-inflammatory activity for the study of diseases associated with neurological disorders.

(Leu31,Pro34)-Peptide YY (human) is a derivative of Peptide YY that acts as a potent and selective Y1 receptor agonist, with a dissociation constant (KD) of 1.0 nM [1].

"(Leu31,Pro34)-Peptide YY (human) (TFA) is the trifluoroacetic acid (TFA) form of (Leu31,Pro34)-Peptide YY (human), a derivative of Peptide YY that acts as a potent and selective Y1 agonist, exhibiting a dissociation constant (K D) of 1.0 nM [1]."

GEP44 is a peptide-biased triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), neuropeptide Y1 receptor (Y1-R), and neuropeptide Y2 receptor (Y2-R). It induces GLP-1R-dependent insulin secretion in rat and human islets by offsetting the actions of Y1-R and GLP-1R agonism, controlled by Y1-R antagonists. Additionally, GEP44 enhances glucose uptake in muscle tissue through Y1-R mediation independent of insulin and significantly reduces food intake and body weight in diet-induced obese rat models. GEP44 is utilized in studies related to obesity and type 2 diabetes.

[D-Trp34]-Neuropeptide Y Acetate is a potent and selective agonist of neuropeptide Y (NPY) Y5 receptor. [D-Trp34]-Neuropeptide acetate Y is a significantly less potent agonist at the NPY Y1, Y2, Y4, and y6 receptors. [D-Trp34]-Neuropeptide Y Acetate markedly increases food intake in rats.

JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity(pIC50=8.07, human; pIC50=8.22, rat); it exhibits >100-fold selectivity for Y2 versus human Y1/Y4/Y5 receptors.

Y2 Antagonist 36 is a highly potent, soluble and selective antagonist of NPY Y2.

Neuropeptide Y (NPY) (3-36) is a C-terminal fragment of NPY, a neuropeptide involved in controlling appetite, blood pressure, cardiac contractility, and intestinal secretion. NPY (3-36) is an endogenous peptide produced by cleavage of NPY by dipeptidyl peptidase 4 (DPP-4). It binds selectively to the NPY receptor Y2 (Ki = 0.41 nM in CHP 234 cells) over the Y1 receptor, where it does not bind at concentrations up to 1 μM. NPY (3-36) (0.1 nM) increases migration of human umbilical vein endothelial cells (HUVECs) by 80% after 12 hours in an in vitro wound closure assay. NPY (3-36) corresponds to residues 3-36 of the human and rat protein sequence.

Neuropeptide Y (3-36) (human, rat) is a metabolite of neuropeptide Y (NPY) generated by dipeptidyl peptidase-4 (DPP4) and is known as a selective Y2 receptor agonist, effectively reducing the release of norepinephrine via the Y2 receptor [1][2].

Potent, selective and competitive nonpeptide antagonist for the neuropeptide Y Y2 receptor (IC50 = 15 nM). Displays > 650-fold selectivity for NPY Y2 over Y1, Y4 and Y5 receptors. Active in vivo.

BIBP 3226 trifluoroacetate is a mixed non-peptide neuropeptide Y Y1(NPY Y1) and neuropeptide FF (NPFF) receptor antagonist (Kivalues are 1.1, 79, 108, > 1000, > 1000 and >1000 for rNPY Y1, hNPFF2, rNPFF, rNPY Y2, rNPY Y4and rNPY Y5respectively). Produces an anxiogenic-like effect in rats following i.c.v. administration.

Y2-Antagonist-2 is a novel, selective, soluble non-peptidic NPY Y2 receptor antagonist with enhanced CNS exposure.

[D-Trp34]-Neuropeptide Y TFA is a potent and selective agonist for the neuropeptide Y (NPY) Y5 receptor, demonstrating significantly lower potency at the NPY Y1, Y2, Y4, and Y6 receptors. It significantly increases food intake in rats [1] [2].

Neuropeptide Y (3-36) (porcine) acts as an agonist for the Y2 subtype of the neuropeptide Y (NPY) receptor, effectively stimulating feeding behavior in rats. This compound exhibits high selectivity for the Y2 receptor compared to the non-selective Y1/Y2 receptor ligand, Neuropeptide Y 1-36 [1][2][3].

Neuropeptide Y (NPY), a neuropeptide, plays roles in regulating appetite, vasoconstriction, cardiac contractility, and intestinal secretion, acting as an agonist for NPY receptors Y1, Y2, and Y5. Expressed ubiquitously, NPY modulates cellular responses by selectively inhibiting forskolin-induced cAMP accumulation in L-M(TK-) cells expressing rat Y1 or Y2 and in HEK293 cells expressing rat Y5, more so than in cells expressing rat Y4 receptors (EC50s = 0.15, 2.7, 0.66, and >1,000 nM, respectively). Additionally, it elevates perfusion pressure in isolated guinea pig hearts (EC30 = 1.3 nM) and, when administered intracerebroventricularly at 300 pmol/animal, it notably increases food intake in rats.

Peptide YY (PYY) (3-36), human (Peptide YY (3-36)), is a gut hormone peptide that acts as a Y2 receptor agonist to reduce appetite.

Peptide YY (PYY) (3-36), human acetate (126339-09-1 Free base) is a NPY (neuropeptide Y) Y2 receptor agonist that suppresses intestinal fluid secretion and slows colonic transit to inhibit diarrhea in mice.

Potent, selective peptide agonist for the neuropeptide Y Y5 receptor (IC50 values for inhibition of NPY binding to human Y5, Y1, Y2 and Y4 receptors are 0.24, 530, > 500, and 51 nM respectively, Ki at Y5 = 0.1 - 0.15 nM). Stimulates food intake in vivo.

Potent neuropeptide Y (NPY) Y5 receptor agonist (pEC50 values are 7.82, 6.28, 6.44 and > 6 at rat Y5, Y4, Y1 and Y2 receptors respectively) that displays > 26-fold, > 1000-fold and > 1000-fold selectivity over Y1, Y2 and Y4 receptors respectively. Induces

NNC0165-1273 is a peptide YY (PYY3-36) analogue acting as an intestinal hormone. It shows significantly higher affinity for the Y2 receptor compared to the Y1, Y4, and Y5 receptors. NNC0165-1273 effectively induces anorexia and decreases food intake prompted by nocturnal and ghrelin stimulation through increased satiety. It also inhibits the expression of cFos in NPY/AgRP neurons induced by ghrelin. NNC0165-1273 is applicable in anti-obesity therapy research.